Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ABVC Biopharma Inc ABVC

Healthcare Biotechnology
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504... see more

Recent & Breaking News (NDAQ:ABVC)

ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed

GlobeNewswire May 3, 2022

ADHD Clinical Study 1 Step Closer to Complete

Stockhouse Editorial April 29, 2022

ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study

GlobeNewswire April 28, 2022

ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting

GlobeNewswire April 26, 2022

ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results

GlobeNewswire March 31, 2022

ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference

GlobeNewswire March 23, 2022

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

GlobeNewswire February 2, 2022

ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites

GlobeNewswire January 5, 2022

ABVC BioPharma's Vitreous Substitute Vitargus Presented at 14th APVRS Congress

GlobeNewswire December 22, 2021

ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award

GlobeNewswire December 15, 2021

ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement

GlobeNewswire December 9, 2021

ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results

GlobeNewswire November 15, 2021

ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M

GlobeNewswire November 11, 2021

Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites

GlobeNewswire October 27, 2021

ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research

GlobeNewswire October 12, 2021

ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study

GlobeNewswire September 13, 2021

ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments

GlobeNewswire September 1, 2021

ABVC BioPharma Report Updated by Zacks/SCR

GlobeNewswire August 30, 2021

ABVC BioPharma Provides Vitargus® Update

GlobeNewswire August 26, 2021